Evaluation of bioactive compounds from Boswellia serrata against SARS-CoV-2

Roy, Arpita; Menon, Tarunya

doi:10.1007/s42535-021-00318-7

Cited by 14 publications

(10 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many researchers are working on herbal medicine to prove its effectiveness in a variety of diseases including COVID-19 [5][6][7][8][9][10][11][12][13][14]. It is well documented that herbal medicine has proven its role in the treatment of inflammation, obesity, cancer, diabetes mellitus, etc.…”

Section: Introductionmentioning

confidence: 99%

Unani Formulation Habb-e-Suranjan: A Treasure of Biological Activities

Tu¹,

Aejazuddin²,

Khan³

et al. 2022

BioMed Research International

Self Cite

View full text Add to dashboard Cite

Habb-e-Suranjan (HES), an Unani formulation, has been studied for its anti-inflammatory properties in both in vitro and in vivo experiments. HES is recommended for arthritis, gout, and joint pain. The current endeavor is an attempt to put it to the test and verify its efficacy scientifically. It was tested for DPPH, hydroxyl, and nitric oxide scavenging activities. It was shown that HES had the greatest TAC and FRAC values when compared to catechin and ascorbic acid. HES exhibited DPPH and hydroxyl radical scavenging activity that was dose-dependent. Incubation of sodium nitroprusside solutions in PBS at 25°C for 150 min resulted in the production of nitric oxide. Nitric oxide production was effectively decreased by HES. Anti-inflammatory medications boosted the migration of PMN cells toward the chemoattractant FMLP in an agarose experiment of PMN chemotaxis. In carrageenan-induced rat paw edema, in the HES-treated group, paw thickness was 3.021 ± 0.084 at t = 0 , but it showed an increase in paw inflammation after one hour, i.e., 3.195 ± 0.082 cm which again showed a decrease in paw thickness up to 4th hour, i.e., 3.018 ± 0.078 , 2.98 ± 0.032 , and 2.684 ± 0.061 at t = 2 , 3, and 4, respectively. It showed again getting back to the normal thickness of paw at t = 24 hrs, i.e., 3.029 ± 0.118 cm. It is concluded that the formulation is potent enough and can be used effectively for the treatment of inflammation and associated health issues. Moreover, there is much scope to evaluate its effectiveness using different in vitro and in vivo models.

show abstract

Section: Introductionmentioning

confidence: 99%

Unani Formulation Habb-e-Suranjan: A Treasure of Biological Activities

Tu¹,

Aejazuddin²,

Khan³

et al. 2022

BioMed Research International

Self Cite

View full text Add to dashboard Cite

show abstract

“…These compounds bind at the H1-H2 binding pocket Ahmad et al ( 2021 ) Natural antioxidants including glycyrrhizin and its metabolite 18-glycyrrhetinic acid Molecular docking, and MD simulations Glycyrrhizin was found as the best ligand showing strong inhibition of five SARS-CoV-2 proteins Glycyrrhizin and its metabolite 18-glycyrrhetinic acid have shown a strong binding affinity for MPro, helicase, RdRp, spike, and E-channel proteins, while a flavonoid Baicalin also strongly binds against PLpro and RdRp Rehman et al ( 2021 ) 56 licorice compounds Silico interaction of main licorice components against SARS-CoV-2 infection Glycyrrhizic acid, considered as a licorice major active ingredient, have a significant antiviral effects Glycyrrhizic acid have the highest affinity to all targets Maddah et al ( 2021 ) β-Boswellic acid and glycyrrhizic acid comparing with many compounds Molecular docking studies to identify binding of medicinal metabolites with SARS-CoV-2 E protein Out of screened compounds, β-boswellic acid (B. serrata) was found to be most suitable, along with glycyrrhizic acid (G. glabra) antiviral activities against enveloped viruses They are strong SARS-CoV-2 E protein inhibitors Fatima et al ( 2022 ) Bioactive compounds from Boswellia serrata Computational method. AutoDock and PATCHDOCK It was found that Euphane possesses most significant inhibitory potential against all of four receptors of virus The top five ligands, bioactive compounds, bind to the catalytic dyad amino acid residues of Mpro by different bonding interactions Roy and Menon ( 2022 ) Acetyl‐11‐keto‐β‐boswellic acid (AKBA), 11‐keto‐β‐boswellic acid (KBA), and β‐boswellic acid (BBA) Molecular modeling and bioinformatics BAs have been reported to possess antiviral properties as antiviral drugs The data of this bioinformatics study suggest that BAs target SARS‐CoV‐2 viruses on an atomic scale on three functional proteins, which in turn are responsible for human cell adhesion or viral RNA replication Caliebe et al ( 2021 ) Alpha-boswellic acid (ABA) and beta-boswellic acid (BBA) which are active components Docking st...…”

Section: Resultsmentioning

confidence: 99%

Glycyrrhizin and boswellic acids, the golden nutraceuticals: multitargeting for treatment of mild–moderate COVID-19 and prevention of post-COVID cognitive impairment

2022

View full text Add to dashboard Cite

Breakthrough infections have been reported in fully vaccinated persons. Furthermore, rebound symptoms have been reported following the new FDA granted emergency use to combat SARS-CoV-2. Glycyrrhizin (GR) and boswellic acids (BAs) combination has been shown to have highly successful actions against COVID-19 in our recent clinical trial. However, the study is limited by the small sample size, and therefore, the aim of this article is to comprehensively evaluate recent evidence on the efficacy of GR and BAs in preventing the development of COVID-19 in patients with mild and moderate infections and in preventing post-COVID-19 cognitive impairment, which is the most important symptom after recovery from Covid-19 disease. We have reviewed and discussed information published since the outbreak of the COVID-19 pandemic until July 2022 on preclinical (in vivo, in vivo and bioinformatics) and clinical studies related to the antiviral, anti-inflammatory and immunomodulatory activity of Gr and BAs. Sixteen studies were performed to determine the efficacy of GR against SARS-CoV-2. Ten studies were used primarily for in vitro and in vivo assays and six used molecular docking studies. However, the antiviral activity of BAs against SARS-CoV-2 was determined in only five studies using molecular modeling and bioinformatics. All these studies confirmed that GR n and BAs have strong antiviral activity and can be used as a therapeutic agent for COVID-19 and as a protective agent against SARS-CoV-2. They may act by inhibiting the main protease SARS-CoV-2 (Mpro) responsible for replication and blocking spike protein-mediated cell entry. Only seven rigorously designed clinical trials regarding the usefulness of GR, BAs or their combinations in the treatment of COVID-19 have been published as of July 2022. Although there is no clinical study regarding the treatment of cognitive impairment after COVID-19 that has been published so far, several preclinical and clinical studies have demonstrated the potential effect of GR and BAs in the prevention and treatment of cognitive impairment by inhibiting the activity of several molecules that activate inflammatory signaling pathway. In conclusion, the findings of our study documented the beneficial use of GR and BAs to treat SARS-CoV-2 and its variants and prevent post-COVID cognitive impairment. However, it warrants further studies with a larger randomized sample size to ensure that the studies have sufficient evidence of benefits against COVID-19 and post-COVID-19 symptoms.

show abstract

“…Recently, in a theoretical study, Kadhim et al ( 2021 ) proposed that alpha-Boswellic acid (ABA) and beta-Boswellic acid (BBA) may inhibit the SARS-CoV-2 virus. In another study, using the computational method, 26 bioactive compounds from Boswellia serrata showed activity against SARS-CoV-2 (Roy and Menon 2021 ). Furthermore, in bioinformatic studies, BA shows high affinity for binding to three functional proteins of SARS-CoV-2 responsible for adhesion and virus replication, as do antiviral agents (Caliebe et al 2021 ).…”

Section: Discussionmentioning

confidence: 99%

Advancing combination treatment with glycyrrhizin and boswellic acids for hospitalized patients with moderate COVID-19 infection: a randomized clinical trial

et al. 2022

View full text Add to dashboard Cite

Recent evidence points to a potential therapeutic role for glycyrrhizin(GR) and boswellic acids (BA) in the treatment of COVID-19 but conclusive evidence is lacking. Our aim is to investigate the efficacy of GR + BA versus placebo for the treatment of hospitalized patients with moderate SARS-CoV-2 or COVID-19 variants infection. The current study is a randomized, double-blind, placebo-controlled, single-center trial. Patients with SARS-CoV-2 or COVID-19 variants diagnosed by PCR test who were admitted to Sohag University hospital were eligible if they were at least 18 years of age and had moderate symptoms. Patients were randomly assigned to receive oral GR capsule (60 mg) and BA (200 mg) twice daily for 14 days or a matching placebo. All patients also received treatment with the institutional protocol for COVID-19. The primary outcome was mortality and time to recovery. Secondary outcome was clinical status score, 14 days after receiving study drugs. Adverse events from use of study drugs have been evaluated for up to 14 days. The trial is registered at ClinicalTrials.gov (Identifier NCT04487964). During the 6-month enrollment period (June-November, 2021) only 50 patients (54% women; median age 60 years, IQR 54–65) met eligibility and were randomly assigned. Evaluation of the primary outcome at 14 days showed that there were five deaths in the placebo group and no deaths in the GR + BA group. With regard to recovery time, it was significantly shorter (p = 0.0001) in the group receiving GR + BA capsule compared to the placebo group (median 7.0; IQR 6.0–8.0 days vs. median 12.5; IQR 12–20 days). Clinical status on the ordinal score scale as a secondary outcome showed a significant difference between the GR + BA group (median (IQR) score, 2 [2–3]) and placebo groups (mean (IQR) score, 3 [3–5.5]). There was a significant decrease in CRB (p = 0.000041) in GR + BA compared with the placebo group. In conclusion, this safe, inexpensive, antiviral, immunomodulating and anti-inflammatory combination may be considered for use in mild to moderate infections of SARS-CoV-2 or COVID-19 variants. The study is limited by the small sample size; therefore, larger randomized trials are required.

show abstract

Evaluation of bioactive compounds from Boswellia serrata against SARS-CoV-2

Cited by 14 publications

References 32 publications

Unani Formulation Habb-e-Suranjan: A Treasure of Biological Activities

Unani Formulation Habb-e-Suranjan: A Treasure of Biological Activities

Glycyrrhizin and boswellic acids, the golden nutraceuticals: multitargeting for treatment of mild–moderate COVID-19 and prevention of post-COVID cognitive impairment

Advancing combination treatment with glycyrrhizin and boswellic acids for hospitalized patients with moderate COVID-19 infection: a randomized clinical trial

Contact Info

Product

Resources

About